Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
88.15
+2.19 (2.55%)
Oct 15, 2025, 4:00 PM EDT - Market closed
Incyte Revenue
Incyte had revenue of $1.22B in the quarter ending June 30, 2025, with 16.46% growth. This brings the company's revenue in the last twelve months to $4.58B, up 18.87% year-over-year. In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth.
Revenue (ttm)
$4.58B
Revenue Growth
+18.87%
P/S Ratio
3.72
Revenue / Employee
$1,752,005
Employees
2,617
Market Cap
17.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
INCY News
- 13 hours ago - 3 Biotech Stocks I Am Accumulating - Seeking Alpha
- 3 days ago - Data from Incyte's TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025 - Business Wire
- 7 days ago - Incyte to Report Third Quarter Financial Results - Business Wire
- 9 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 18 days ago - China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication - GlobeNewsWire
- 21 days ago - Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 21 days ago - Cramer reveals 5 undervalued stocks that are must-own heading into 2026 - Invezz
- 23 days ago - Jim Cramer names inexpensive stocks worth buying as the S&P 500 heads higher - CNBC